ClinicalTrials.gg
CompletedNCT02145065PAXUpdated Aug 7, 2018

First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)

An interventional study of Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland) and Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland) in Peripheral Artery Disease and Femoropopliteal Artery Disease, sponsored by Balton Sp.zo.o.. Completed at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-07.

Sponsored by Balton Sp.zo.o. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.

Enrollment
20th of 28
66 · median 220
Started
2014
with 1 other
No phase
16 of 31
4 open now
Registered
9th of 31
by date
Lead sponsor
3 of 31
Balton Sp.zo.o.

Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is the 20th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2014, is one of 16 with no phase, and was the 9th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Peripheral Arterial Disease with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment of femoropopliteal artery disease.

Read the detailed description

Although clinically effective, the manufacturing process of first generation PCB coatings contributed to inconsistent drug concentrations, particulate formations on the balloon surface and their shedding during the interventional procedures. As a consequence developments of new PCB coatings have been proposed to address consistency, uniformity, small particle drug coverage, which may potentially contribute to improved vessel healing profile and improved clinical outcomes. Nevertheless, data on the safety and efficacy of this novel coating developments in the clinical setting remain limited. Previously in the experimental model, the investigators reported that delivery of paclitaxel via a novel mcPCB resulted in low long-term tissue retention of paclitaxel, however displayed reduced neointimal proliferation and favorable healing profile. Therefore in current clinical trial the investigators will address the feasibility and safety of the mcPCB (PAK, Balton) in the treatment of femoropopliteal restenotic disease in a prospective, randomized manner when compared to plain balloon angioplasty (PBA). The efficacy analysis will be observational and evaluated post-hoc, with no prespecified criteria.

03

Conditions studied

  • Peripheral Artery Disease
  • Femoropopliteal Artery Disease

Keywords

  • paclitaxel coated balloon
  • restenosis
  • Femoropopliteal artery disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 y.o.
  • Claudication in Rutherford Class 1-5,
  • Lesion in the femoropopliteal artery defined as >50% and \< 99% diameter stenosis with length of up to 10 cm in vessel diameter of 3-7 mm
  • Chronic total occlusions of length less than 100 mm
  • Ability to cross the lesions with a guidewire.

Exclusion criteria

Exclusion Criteria:

  • Critical acute or chronic limb ischemia
  • Acute coronary syndrome
  • Chronic kidney disease stage III-V
  • Restenotic lesion
  • Femoropopliteal graft
  • Known allergy to clopidogrel or aspirin
  • History of stroke within past 6 months
  • Age > 80 y.o.
  • \< 2 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    Plain Balloon Angioplasty

    Plain Balloon Angioplasty

    Device: Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)

  • Experimental
    microcrystalline Paclitaxel Coated Balloon (PAK)

    plain balloon angioplasty followed by mcPCB dilation

    Drug: Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)

Interventions

  • DrugLocal drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)
  • DevicePlain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)
06

What researchers measure

Primary outcomes

  1. Angiographic late lumen loss

    Time frame: 6 months

Secondary outcomes

  1. Safety - Device related adverse events

    Time frame: 30 days, 6 months

  2. Critical limb ischemia

    Time frame: 30 days, 6 months

  3. Device Success

    Successful delivery and deployment of the first inserted study device (in overlapping setting a successful delivery and deployment of the first and second study device) at the intended target lesion and successful withdrawal of the study device with attainment of final residual stenosis of less than 30% of the target lesion by quantitative vessel angiography (QVA).

    Time frame: at procedure

  4. Target Lesion Revascularization

    Time frame: 6, 12, 24 months

  5. Target vessel revascularization

    Time frame: 6, 12, 24 months

  6. Primary patency of treated segment

    Time frame: 6, 12, 24 months

  7. Treated limb amputation

    Time frame: 30 days, 6 months

Other outcomes

  1. Change in ankle-brachial index

    Time frame: pre-procedure, 3,6 and 12 months

  2. Change in Walking Impairment Questionnaire (WIQ)

    Time frame: pre procedure, 3, 6 and 12 months

  3. Flow velocity in doppler ultrasonography

    Time frame: 3, 6 and 12 months

07

Study locations

1 site
  • Lesser-Poland Cardiovascular Center of American Heart of Poland
    Chrzanów, 32-500, Poland
08

References and documents

Publications

  • Buszman PP, Milewski K, Zurakowski A, Pajak J, Jelonek M, Gasior P, Peppas A, Tellez A, Granada JF, Buszman PE. Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. Catheter Cardiovasc Interv. 2014 Feb;83(2):325-33. doi: 10.1002/ccd.24982. Epub 2013 Oct 23. PubMed 23703720 ↗
  • Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008 Feb 14;358(7):689-99. doi: 10.1056/NEJMoa0706356. PubMed 18272892 ↗
  • Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008 Sep 23;118(13):1358-65. doi: 10.1161/CIRCULATIONAHA.107.735985. Epub 2008 Sep 8. Erratum In: Circulation. 2008 Oct 14;118(16):e670. PubMed 18779447 ↗
  • Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. doi: 10.1056/NEJMoa061254. Epub 2006 Nov 13. PubMed 17101615 ↗
  • Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014 Jan;7(1):10-9. doi: 10.1016/j.jcin.2013.05.022. PubMed 24456716 ↗
  • Nowakowski P, Uchto W, Hrycek E, Kachel M, Ludyga T, Polczyk F, Zurakowski A, Kazmierczak P, Granada JF, Nowakowska I, Kiesz RS, Milewski KP, Buszman PE, Buszman PP. Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: Three-year outcomes of the randomized BIOPAC trial. Vasc Med. 2021 Aug;26(4):401-408. doi: 10.1177/1358863X20988360. Epub 2021 Mar 9. PubMed 33686879 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Sep 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2014
First posted
May 22, 2014
Start
Sep 2014
Primary completionActual
Sep 2017
CompletionActual
Oct 2017
Last update
Aug 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02145065
Lead sponsor
Balton Sp.zo.o.
Collaborators
American Heart of Poland
Responsible party
Sponsor
First posted
May 22, 2014
Start date
Sep 2014
Primary completion
Sep 2017
Completion
Oct 2017
Last update
Aug 7, 2018

Study contacts

Przemysław Nowakowski, M.D., PhD
principal investigator · American Heart of Poland, Katowice, Poland
Piotr P Buszman, M.D., PhD
principal investigator · American Heart of Poland, Katowice, Poland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion